Novelix Pharmaceuticals Limited has successfully completed a preferential share allotment to investor Mallela Venkataramna Reddy, with formal regulatory disclosures submitted to BSE Limited on February 17, 2026. The transaction involved the allotment of 3,30,000 equity shares representing 1.66% of the company's share capital, completed on February 12, 2026.

Regulatory Compliance and Documentation

The company has submitted comprehensive disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The formal intimation was filed by Whole-time Director Venkateshwarlu Pulluru to BSE Limited, where Novelix Pharmaceuticals shares are listed under scrip code 536565.

Shareholding Structure Changes

The preferential allotment has significantly altered the investor's stake in the company. The detailed shareholding pattern shows substantial increase in Reddy's ownership:

Company Capital Structure Enhancement

The preferential allotment has resulted in an expansion of Novelix Pharmaceuticals' equity share capital structure:

Corporate Governance and Transparency

The transaction demonstrates adherence to regulatory requirements with proper documentation submitted to both BSE Limited and the company's board of directors. Novelix Pharmaceuticals, formerly known as Trimurthi Limited, maintains its registered office in Hyderabad, Telangana, and operates under CIN L67120TG1994PLC018956.

This preferential allotment represents investor confidence in Novelix Pharmaceuticals' business prospects and provides the company with additional capital for operational and growth requirements while maintaining full regulatory compliance.

Novelix Pharmaceuticals Limited (formerly known as trimurthi Limited) has submitted revised unaudited financial results for the quarter ended December 31, 2025, to the BSE. The revision was necessitated due to typographical errors in the auditor's limited review report, with the corrected version submitted on February 14, 2026.

Financial Performance Overview

The company demonstrated robust financial performance during Q3FY26, with significant improvements across key metrics compared to the corresponding quarter of the previous year.

Quarterly and Nine-Month Performance

The company's performance showed consistent improvement on a sequential basis as well. Total income increased from ₹3,639.14 lakhs in Q2FY26 to ₹4,840.27 lakhs in Q3FY26. For the nine months ended December 31, 2025, the company reported total income of ₹10,714.52 lakhs compared to ₹987.35 lakhs in the corresponding nine-month period of the previous year.

Earnings Per Share and Capital Structure

The company's earnings per share (EPS) for continuing operations showed improvement, with basic EPS at ₹0.58 for Q3FY26 compared to ₹0.15 in Q3FY25. The paid-up equity share capital increased to ₹1,721.50 lakhs as of December 31, 2025, from ₹995.00 lakhs in the previous year.

Business Focus and Operations

Novelix Pharmaceuticals operates in a single business segment focused on pharmaceutical research, analysis, manufacturing, and trading of active pharmaceutical ingredients (bulk drugs). The company has discontinued activities in investment in shares, trading in shares, foods, and finance segments to concentrate on its core pharmaceutical operations.

Regulatory Compliance and Approval

The unaudited financial results were reviewed by CVS Balachandra Rao & Co., Chartered Accountants, and received a clean limited review report. The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 12, 2026. The board meeting commenced at 5:00 PM and concluded at 5:30 PM, with the results being made available on the company's website at https://novelixpharma.com .